# Slovakia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Slovakia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Slovakia (SVK)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $249.0M
- Products: 37
- Buyer markets: 29
- Average CAGR: +16.6%
- Global sector size: $762.2B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $305.8B | $176.5M | $115.3B | +21.0% | 21 | +0.1% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $168.4B | $31.7M | $69.5B | +37.9% | 17 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $29.0B | $171.9K | $32.1B | +67.0% | 4 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $45.8K | $23.0B | +53.3% | 3 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $30.5B | $6.2M | $17.3B | +12.2% | 7 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $23.1B | $631.1K | $17.2B | +6.4% | 8 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $126.8K | $16.8B | -0.4% | 3 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $12.1B | $22.5K | $16.0B | -8.4% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $18.0M | $15.9B | +24.2% | 8 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $13.3B | $2.4M | $13.1B | -24.1% | 4 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $1.7M | $10.7B | +20.8% | 3 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $10.1B | $7.5M | $8.5B | +12.5% | 3 | +0.1% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $884.5K | $8.5B | +7.9% | 3 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $16.8B | $5.9K | $7.0B | -1.2% | 3 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $1.1M | $6.3B | +10.6% | 3 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $22.2K | $4.8B | +35.5% | 1 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $2.4B | $1.5K | $4.2B | -48.7% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $1.8K | $4.1B | -0.6% | 2 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.6B | $217.9K | $3.4B | +64.9% | 2 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $4.2K | $3.3B | -1.2% | 2 | +0.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $3.2B | $1.1M | $3.1B | +26.4% | 1 | +0.1% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $4.6B | $22.5K | $2.9B | -15.0% | 2 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.1B | $3.4K | $2.9B | -6.1% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $804.1 | $2.1B | -11.8% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $7.7K | $2.0B | +1.6% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $79.1K | $2.0B | +9.1% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $21.5 | $1.8B | -45.9% | 1 | +0.0% |
| HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $120.8 | $1.5B | +6.5% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $1.8K | $1.4B | +5.9% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $154.3 | $1.4B | +13.5% | 1 | +0.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $338.5K | $1.3B | +86.0% | 1 | +0.4% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $8.6K | $1.2B | +0.6% | 1 | +0.0% |
| HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $655.8M | $14.8 | $1.2B | -10.9% | 1 | +0.0% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $1.0K | $1.2B | -9.9% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $5.1 | $1.1B | -61.7% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $2.4K | $1.1B | +6.8% | 1 | +0.0% |
| HS 290250 - Cyclic hydrocarbons: styrene | $768.8M | $161.7K | $1.1B | +98.1% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $114.2B calculated opportunity across 17 products.
- Germany (DEU): $41.6B calculated opportunity across 13 products.
- Switzerland, Liechtenstein (CHE): $36.6B calculated opportunity across 4 products.
- Slovenia (SVN): $35.7B calculated opportunity across 5 products.
- Italy (ITA): $25.1B calculated opportunity across 5 products.
- China (CHN): $24.1B calculated opportunity across 9 products.
- Belgium (BEL): $23.9B calculated opportunity across 5 products.
- Netherlands (NLD): $20.7B calculated opportunity across 6 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Spain (ESP): $11.6B calculated opportunity across 6 products.
- Mexico (MEX): $10.1B calculated opportunity across 5 products.
- Canada (CAN): $9.8B calculated opportunity across 5 products.

## Growth stars

- HS 290250: +98.1% average CAGR, $1.1B calculated opportunity.
- HS 310221: +86.0% average CAGR, $1.3B calculated opportunity.
- HS 300214: +67.0% average CAGR, $32.1B calculated opportunity.
- HS 290919: +64.9% average CAGR, $3.4B calculated opportunity.
- HS 293359: +53.3% average CAGR, $23.0B calculated opportunity.
- HS 300215: +37.9% average CAGR, $69.5B calculated opportunity.
- HS 293379: +35.5% average CAGR, $4.8B calculated opportunity.
- HS 310420: +26.4% average CAGR, $3.1B calculated opportunity.
- HS 300439: +24.2% average CAGR, $15.9B calculated opportunity.
- HS 300490: +21.0% average CAGR, $115.3B calculated opportunity.

## Diversification opportunities

- HS 300490: 21 buyer markets, $115.3B calculated opportunity.
- HS 300215: 17 buyer markets, $69.5B calculated opportunity.
- HS 382499: 8 buyer markets, $17.2B calculated opportunity.
- HS 300439: 8 buyer markets, $15.9B calculated opportunity.
- HS 300212: 7 buyer markets, $17.3B calculated opportunity.
- HS 300214: 4 buyer markets, $32.1B calculated opportunity.
- HS 300220: 4 buyer markets, $13.1B calculated opportunity.
- HS 293359: 3 buyer markets, $23.0B calculated opportunity.
- HS 293399: 3 buyer markets, $16.8B calculated opportunity.
- HS 293719: 3 buyer markets, $16.0B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.